Gimeno F, Postma D S, van Altena R
Asthma Clinic, University of Groningen, The Netherlands.
Chest. 1993 Aug;104(2):467-70. doi: 10.1378/chest.104.2.467.
Slow inspiratory vital capacity (IVC) and forced expiratory volume in 1 s (FEV1) before and after an inhaled beta-agonist are widely used to detect reversible airflow limitation in patients with chronic obstructive lung disease. The measurement of airways resistance (Raw) during quiet breathing with the body plethysmograph is less frequently used. It may well be of importance in clinical emphysema where measurement of FEV1 is confounded by the collapse of the bronchi, which does not occur when measuring Raw during quiet breathing. We assessed whether Rrs, in addition to IVC and FEV1, can be used to gain a better insight into the reversibility with 400 micrograms of fenoterol in patients with clinical emphysema. We studied a group of 51 patients (9 women and 42 men; mean [+/- SD] age, 64.7 [7.7] years) who had a clinical diagnosis of emphysema. Significant reversibility was identified by spirometry (IVC, FEV1) and body plethysmography (Raw) in 20 patients (39 percent). Inspiratory vital capacity alone identified reversibility of airflow limitation in 11 patients (22 percent). In 5 patients (10 percent), the postbronchodilator improvement was seen exclusively in the Raw measurement. In the remaining patients, absence of improvement in spirometric and plethysmographic parameters was found. Subjective improvement occurred to the same extent in patients whose Raw and IVC improved. We concluded that Raw gives important information about the reversibility of airways obstruction in patients with clinical emphysema. Therefore, we suggest that tests during quiet breathing should be part of the routine examination of airways obstruction in patients with "irreversible" obstruction by conventional spirometry.
吸入β受体激动剂前后的慢吸气肺活量(IVC)和一秒用力呼气容积(FEV1)被广泛用于检测慢性阻塞性肺疾病患者的可逆性气流受限。使用体容积描记仪测量静息呼吸时的气道阻力(Raw)则较少被采用。在临床肺气肿中,这可能具有重要意义,因为在测量FEV1时,支气管塌陷会混淆测量结果,而在静息呼吸时测量Raw则不会出现这种情况。我们评估了除IVC和FEV1外,呼吸阻力比(Rrs)是否可用于更好地了解临床肺气肿患者吸入倍氯米松400微克后的可逆性。我们研究了一组51例临床诊断为肺气肿的患者(9名女性和42名男性;平均[±标准差]年龄为64.7[7.7]岁)。通过肺活量测定法(IVC、FEV1)和体容积描记法(Raw)确定20例患者(39%)有显著可逆性。仅吸气肺活量确定11例患者(22%)存在气流受限可逆性。5例患者(10%)仅在Raw测量中出现支气管扩张剂后改善。在其余患者中,肺活量测定和体积描记参数未发现改善。Raw和IVC改善的患者主观改善程度相同。我们得出结论,Raw为临床肺气肿患者气道阻塞的可逆性提供了重要信息。因此,我们建议静息呼吸时的测试应成为常规肺活量测定法显示“不可逆”阻塞的患者气道阻塞常规检查的一部分。